Publications
2024
The Highs and Lows of ADAMTS13 Activity.
Shaw, R. J., Abrams, S. T., Badu, S., Toh, C. -H., & Dutt, T. (2024). The Highs and Lows of ADAMTS13 Activity.. Journal of clinical medicine, 13(17), 5152. doi:10.3390/jcm13175152
2023
Damage-associated cellular markers in the clinical and pathogenic profile of vaccine-induced immune thrombotic thrombocytopenia.
Abrams, S. T., Du, M., Shaw, R. J., Johnson, C., McGuinness, D., Schofield, J., . . . Toh, C. -H. (2023). Damage-associated cellular markers in the clinical and pathogenic profile of vaccine-induced immune thrombotic thrombocytopenia.. Journal of thrombosis and haemostasis : JTH, S1538-7836(23)00873-5. doi:10.1016/j.jtha.2023.12.008
Evolving Pathophysiological and Clinical Care Considerations in iTTP
Shaw, R. (2023, October 5). Evolving Pathophysiological and Clinical Care Considerations in iTTP.
Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria
Shaw, R. J., Doyle, A. J., Millen, E. A., Stowe, J., Tessier, E., Andrews, N., & Miller, E. (2023). Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria. VACCINE, 41(36), 5330-5337. doi:10.1016/j.vaccine.2023.06.006
Integrating psychology services for patients with thrombotic thrombocytopenic purpura: A specialist centre experience.
Shaw, R. J., Bell, J., Poole, J., Feely, C., Chetter, J., & Dutt, T. (2023). Integrating psychology services for patients with thrombotic thrombocytopenic purpura: A specialist centre experience.. EJHaem, 4(3), 872-875. doi:10.1002/jha2.726
2022
Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019
Bull, T. (2022). Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 20(6), 1428-1436. doi:10.1111/jth.15681
Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura
Shaw, R. J., & Dutt, T. (2022). Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura. BRITISH JOURNAL OF HAEMATOLOGY, 197(5), 529-538. doi:10.1111/bjh.18127
A single 1 g/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR 'Flash-Mob' retrospective study incorporating 961 patients
Nicolson, P. L. R., Perry, R., Buka, R. J., Fisher, A., Scott, G., Magill, L., . . . Hill, Q. A. (2022). A single 1 g/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR 'Flash-Mob' retrospective study incorporating 961 patients. BRITISH JOURNAL OF HAEMATOLOGY, 196(2), 433-437. doi:10.1111/bjh.17692
2021
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality
Shaw, R. J., Abrams, S. T., Austin, J., Taylor, J. M., Lane, S., Dutt, T., . . . Toh, C. -H. (2021). Circulating histones play a central role in COVID-19-associated coagulopathy and mortality. HAEMATOLOGICA, 106(9), 2493-2498. doi:10.3324/haematol.2021.278492
COVID-19 and immunothrombosis: emerging understanding and clinical management
Shaw, R. J., Bradbury, C., Abrams, S. T., Wang, G., & Toh, C. -H. (2021). COVID-19 and immunothrombosis: emerging understanding and clinical management. BRITISH JOURNAL OF HAEMATOLOGY, 194(3), 518-529. doi:10.1111/bjh.17664
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab
Schofield, J., Shaw, R. J., Lester, W., Thomas, W., Toh, C. -H., & Dutt, T. (2021). Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 19(8), 1922-1925. doi:10.1111/jth.15363
Real-world experience with caplacizumab in the management of acute TTP
Dutt, T., Shaw, R. J., Stubbs, M., Yong, J., Bailiff, B., Cranfield, T., . . . Scully, M. (2021). Real-world experience with caplacizumab in the management of acute TTP. BLOOD, 137(13), 1731-1740. doi:10.1182/blood.2020007599
ADAMTS13 activity trends in TTP patients with COVID-19 infection
Shaw, R. J., Kenworthy, J., Lawrenson, A., Toh, C. -H., & Dutt, T. (2021). ADAMTS13 activity trends in TTP patients with COVID-19 infection. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 193 (pp. 211). Retrieved from https://www.webofscience.com/
Factors influencing time from initial presentation to start of plasma exchange (PEX) in patients with acute thrombotic thrombocytopenic purpura (TTP)
Bull, T., McCulloch, R., Nicolson, P., Shaw, R. J., Sayar, Z., Langridge, A., . . . Scully, M. (2021). Factors influencing time from initial presentation to start of plasma exchange (PEX) in patients with acute thrombotic thrombocytopenic purpura (TTP). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 193 (pp. 27-28). Retrieved from https://www.webofscience.com/
2020
Circulating Histone Levels Correlate with the Severity of COVID-19 and the Extent of Coagulation Activation and Inflammation
Shaw, R. J., Austin, J., Taylor, J., Dutt, T., Wang, G., Abrams, S. T., & Toh, C. H. (2020). Circulating Histone Levels Correlate with the Severity of COVID-19 and the Extent of Coagulation Activation and Inflammation. In BLOOD Vol. 136. doi:10.1182/blood-2020-142344
Patients with acute thrombotic thrombocytopenic purpura (TTP) should be managed in a critical care setting - A Single TTP Referral Centre Experience
Shaw, R. J., Garth, L., Toh, C. -H., & Dutt, T. (2020). Patients with acute thrombotic thrombocytopenic purpura (TTP) should be managed in a critical care setting - A Single TTP Referral Centre Experience. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 189 (pp. 268). Retrieved from https://www.webofscience.com/
2019
Attacking Infection When the Defences Are Down: An Audit of the Management of Sepsis in Haemato-oncology Patients in a Tertiary centre
D'Arienzo, P., Shaw, R. J., Johnstone, M., Salim, R., & Turtle, L. (2019). Attacking Infection When the Defences Are Down: An Audit of the Management of Sepsis in Haemato-oncology Patients in a Tertiary centre. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 161-162). Retrieved from https://www.webofscience.com/
Forward View in Multiple Myeloma: Streamlining Care at Diagnosis, a Tertiary Centre Experience
Shaw, R. J., Johnstone, M., Simon, C., & Brearton, G. (2019). Forward View in Multiple Myeloma: Streamlining Care at Diagnosis, a Tertiary Centre Experience. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 181-182). Retrieved from https://www.webofscience.com/
2018
Do Immune-Mediated TTP Patients Presenting with No Detectable ADAMTS13 Antibody Represent a Unique Clinical Phenotype?
Shaw, R. J., Lawrenson, A., Downey, C., Moss, K., & Dutt, T. (2018). Do Immune-Mediated TTP Patients Presenting with No Detectable ADAMTS13 Antibody Represent a Unique Clinical Phenotype?. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-111942
Trends in ADAMTS13 Activity Testing over the Last 7 Years in a Single UK TTP Specialist Centre
Moss, K., Downey, C., Lawrenson, A., Dutt, T., & Shaw, R. J. (2018). Trends in ADAMTS13 Activity Testing over the Last 7 Years in a Single UK TTP Specialist Centre. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-119331
Radioactive phosphorus (32P) for the treatment of thrombocytosis in patients with myeloproliferative neoplasms: a UK single centre retrospective audit
Shaw, R. J., Seshadri, N., & Butt, N. M. (2018). Radioactive phosphorus (32P) for the treatment of thrombocytosis in patients with myeloproliferative neoplasms: a UK single centre retrospective audit. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 64-65). Retrieved from https://www.webofscience.com/
2016
Continuation of eculizumab in atypical haemolytic syndrome (aHUS) patients without renal recovery or an identified complement defect
Shaw, R. J., Jones, C. K., & Dutt, T. (2016). Continuation of eculizumab in atypical haemolytic syndrome (aHUS) patients without renal recovery or an identified complement defect. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 59-60). Retrieved from https://www.webofscience.com/
2014
Unforeseen risk in the treatment of severe community-acquired pneumonia with narrow-spectrum antibiotics
Folb, J., Potter, L., Roberts, S., Shaw, R., Kent, W., & Vaudrey, K. (2014). Unforeseen risk in the treatment of severe community-acquired pneumonia with narrow-spectrum antibiotics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(7), 2013-2014. doi:10.1093/jac/dku056